JP2018516244A - 肺がんを処置するための方法 - Google Patents

肺がんを処置するための方法 Download PDF

Info

Publication number
JP2018516244A
JP2018516244A JP2017554475A JP2017554475A JP2018516244A JP 2018516244 A JP2018516244 A JP 2018516244A JP 2017554475 A JP2017554475 A JP 2017554475A JP 2017554475 A JP2017554475 A JP 2017554475A JP 2018516244 A JP2018516244 A JP 2018516244A
Authority
JP
Japan
Prior art keywords
fra
antibody
seq
patient
expression level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017554475A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516244A5 (enExample
Inventor
ダニエル ジョン オシャネシー,
ダニエル ジョン オシャネシー,
Original Assignee
モーフォテック, インコーポレイテッド
モーフォテック, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モーフォテック, インコーポレイテッド, モーフォテック, インコーポレイテッド filed Critical モーフォテック, インコーポレイテッド
Publication of JP2018516244A publication Critical patent/JP2018516244A/ja
Publication of JP2018516244A5 publication Critical patent/JP2018516244A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2017554475A 2015-04-17 2016-04-14 肺がんを処置するための方法 Pending JP2018516244A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562149184P 2015-04-17 2015-04-17
US62/149,184 2015-04-17
PCT/US2016/027497 WO2016168440A1 (en) 2015-04-17 2016-04-14 Methods for treating lung cancer

Publications (2)

Publication Number Publication Date
JP2018516244A true JP2018516244A (ja) 2018-06-21
JP2018516244A5 JP2018516244A5 (enExample) 2019-03-28

Family

ID=55809240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017554475A Pending JP2018516244A (ja) 2015-04-17 2016-04-14 肺がんを処置するための方法

Country Status (13)

Country Link
US (1) US20180125970A1 (enExample)
EP (1) EP3283886B1 (enExample)
JP (1) JP2018516244A (enExample)
KR (1) KR20170137848A (enExample)
CN (1) CN107624071A (enExample)
AU (1) AU2016248222A1 (enExample)
BR (1) BR112017022320A2 (enExample)
CA (1) CA2983126A1 (enExample)
IL (1) IL255079A0 (enExample)
MX (1) MX2017013390A (enExample)
RU (1) RU2718780C9 (enExample)
SG (1) SG11201708546UA (enExample)
WO (1) WO2016168440A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116592A2 (en) * 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
US20170247449A1 (en) * 2014-06-06 2017-08-31 Kyowa Hakko Kirin Co., Ltd Therapeutic method and medicament for cancer patients by folr1-targeting drug and an antagonist for folic acid metabolism
US10822410B2 (en) 2016-11-23 2020-11-03 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
US11873335B2 (en) 2018-03-13 2024-01-16 Phanes Therapeutics, Inc. Anti-folate receptor 1 antibodies and uses thereof
CA3103369A1 (en) * 2018-06-18 2019-12-26 Medimmune Limited Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
CN110221052B (zh) * 2019-06-17 2022-09-23 昆山德诺瑞尔生物科技有限公司 Ppfibp1蛋白在制备肝癌术后预后评估试剂盒中的应用
AU2023229967A1 (en) * 2022-03-11 2024-08-08 Astrazeneca Ab A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1716179A2 (en) * 2004-02-12 2006-11-02 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
WO2006116592A2 (en) * 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
GB0718167D0 (en) * 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
CA2816991C (en) 2010-11-05 2020-06-09 Morphotek Inc. Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
EP3330291B1 (en) 2011-07-15 2020-09-02 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EXPERT OPIN INVESTIG DRUGS., vol. 24(1), JPN6019047001, January 2015 (2015-01-01), pages 125 - 132, ISSN: 0004165962 *

Also Published As

Publication number Publication date
RU2017136863A3 (enExample) 2019-08-21
RU2017136863A (ru) 2019-05-17
SG11201708546UA (en) 2017-11-29
WO2016168440A1 (en) 2016-10-20
CN107624071A (zh) 2018-01-23
RU2718780C2 (ru) 2020-04-14
MX2017013390A (es) 2018-06-13
US20180125970A1 (en) 2018-05-10
RU2718780C9 (ru) 2020-07-08
BR112017022320A2 (pt) 2018-07-24
EP3283886A1 (en) 2018-02-21
AU2016248222A1 (en) 2017-11-09
IL255079A0 (en) 2017-12-31
KR20170137848A (ko) 2017-12-13
EP3283886B1 (en) 2020-01-15
CA2983126A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
EP2438442B1 (en) Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
RU2718780C9 (ru) Способы лечения рака легкого
US20190202930A1 (en) Methods for treatment of ovarian cancer
US10221240B2 (en) Methods for treatment of gastric cancer
US20140005059A1 (en) Biomarkers for cancer
US20190154694A1 (en) Detection and treatment of cancer
WO2022154037A1 (ja) がんの予後バイオマーカー
KR20180013878A (ko) 렌바티닙 및 에베로리무스를 포함하는 병용 요법을 위한 생체표지
WO2019064073A1 (en) USE OF CA125 FOR PREDICTING ANTI-MESOTHELIC TREATMENT OF MESOTHELIOMES
CN110546510A (zh) 预后方法和在所述方法中有用的试剂盒

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20181109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191202

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20191211

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20191219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191211

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200623